Previous close | 26.00 |
Open | 26.00 |
Bid | 39.70 |
Ask | 42.60 |
Strike | 30.00 |
Expiry date | 2024-06-21 |
Day's range | 24.00 - 26.00 |
Contract range | N/A |
Volume | |
Open interest | 605 |
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?